Forest Labs News

The Federal Reserve on Wednesday said risks to the outlook for the U.S. economy and job market had eased since last fall, but it said it would keep buying $85 billion in bonds per month given the still-high level of unemployment.

Ironwood Pharmaceuticals, Inc. recently announced that it has launched Constella in collaboration with Almirall, S.A. in Europe.

Forest Laboratories, Inc. recently announced the launch of its Alzheimer's drug, Namenda XR, in the US.

The firm currently has a "buy" rating on the stock. Cantor Fitzgerald's price objective would suggest a potential upside of 16.85% from the stock's previous close.

Ironwood Pharmaceuticals Inc. of Cambridge and its European partner, Almirall S.A. of Spain, said that a new Ironwood drug for irritable bowel syndrome with constipation is now available in Germany, the UK, and the Nordic countries.

Forest Laboratories, Inc. announced today that NAMENDA XR once-daily formulation is now available in pharmacies throughout the United States.

Jefferies Group's price target indicates a potential upside of 20.51% from the stock's previous close.

Francis I. Perier - Chief Financial Officer, Executive Vice President of Finance & Administration and Member of Disclosure, Legal Compliance & Risk Management Committee All right, we're going to start, everybody.

Meanwhile, a Viola, New York man is outraged that his private information is being collected by someone other than advertisers.

Forest Laboratories Inc said on Tuesday it will add a representative of Carl Icahn as an independent member to its board, averting a new proxy battle with the billionaire investor.

This report provides information on the therapeutic development for Acute Inflammation, complete with latest updates, and special features on late-stage and discontinued projects.

Forest Laboratories Inc is trying to avert yet another bitter proxy battle with billionaire investor Carl Icahn ahead of its annual investor meeting this summer, according to two sources familiar with the situation.

Check below for free stories on APA;BHI;CTXS;COP;CRM;RHP;TKR;DCO;ACC;LMOS;INFA;JOEZ;FRX;BBG;KED;QEP;BBBY the last two weeks.

The firm currently has a $46.00 target price on the stock. Argus' price objective would indicate a potential upside of 14.74% from the stock's previous close.

Carl Icahn lost a proxy battle in 2011 to leverage his 10% ownership stake into four seats on Forest Lab's board.

TechNavio's analysts forecast the Global Alzheimer's Drugs market to grow at a CAGR of 3.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population.

Shares of Ironwood Pharmaceuticals Inc. rose Friday after a Wedbush analyst upgraded the stock, saying growth in prescriptions for the company's bowel drug Linzess has been better than he expected.

The analysts wrote, "Forest Laboratories has been upgraded by TheStreet Ratings from hold to buy.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Around the same time that Howard Solomon decided that he will soon retire as the long-standing ceo at Forest Laboratories, the drugmaker received a subpoena from the US Department of Justice concerning its Turdorza Pressair treatment for chronic obstructive ... (more)

Activist investors are no stranger to the health-care sector, an industry known for binary events and buyouts.